F. Hoffmann-La Roche AG

Switzerland

About Roche

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry nine years in a row by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2017 employed about 94,000 people worldwide. In 2017, Roche invested CHF 10.4 billion in R&D and posted sales of CHF 53.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

1 October 2017 - 30 September 2018

Region: Global
Subject/journal group: All

The table to the right includes counts of all research outputs for F. Hoffmann-La Roche AG published between 1 October 2017 - 30 September 2018 which are tracked by the Nature Index.

Hover over the donut graph to view the FC output for each subject. Below, the same research outputs are grouped by subject. Click on the subject to drill-down into a list of articles organized by journal, and then by title.

Note: Articles may be assigned to more than one subject area.

AC	FC
126	51.49

Outputs by subject (FC)

Subject	AC	FC
Life Sciences	100	39.38
Cancer Cell	2	0.42
Cancer Research	3	1.43
Cell	3	1.12
Cell Host & Microbe	1	0.03
Cell Metabolism	2	1.11
Cell Stem Cell	2	0.07
Genome Research	1	0.20
Journal of Biological Chemistry	8	3.20
Journal of Cell Biology	2	2
Journal of Clinical Investigation	2	0.17
Journal of Experimental Medicine	3	2.89
Journal of Neuroscience	3	1.55
Molecular Cell	3	2.04
Nature	6	4.34
Nature Cell Biology	1	0.04
Nature Chemical Biology	1	0.94
Nature Communications	22	5.28
Nature Genetics	2	0.04
Nature Immunology	5	1.51
Nature Medicine	3	0.81
Nature Methods	1	0.95
Nature Neuroscience	1	0.05
PLOS Biology	1	0.05
Proceedings of the National Academy of Sciences of the United States of America	10	6.09
Science	2	0.06
Science Translational Medicine	3	0.42
The EMBO Journal	1	0.45
eLife	6	2.12
Chemistry	30	13.51
Physical Sciences	3	0.06

Highlight of the month

Bacteria-killing antibody drug

© VICTOR HABBICK VISIONS/SCIENCE PHOTO LIBRARY/Getty

An antibody drug that targets and kills Escherichia coli bacteria could help overcome the scourge of antibiotic-resistant superbugs.

Researchers from Genentech, a Roche subsidiary, have discovered a monoclonal antibody that selectively inhibits a protein that E. coli needs to properly fold and integrate other essential proteins on the bacterial surface.

On binding, the antibody disrupted the integrity of the outer membrane, leading to bacterial death. And even at sub-lethal doses, the antibody made the outer membrane more permeable to certain antibiotics, helping to lower the barrier for these other drugs to act.

The findings could pave the way for a new class of antibody-based therapeutics for fighting superbug infections. They also reveal a bacterial weakness that could be targeted with new types of small-molecule antibiotics.

Supported content